摘要
长春长生生物科技有限责任公司疫苗记录造假事件持续发酵,其上市母公司长生生物科技股份有限公司已被带上＂ST＂帽子,随时有退市风险。但企业造假的损失不该由股民买单唯众怒不可犯。长春长生生物科技有限责任公司疫苗记录造假将其上市母公司长生生物科技股份有限公司拖入深渊。截至2018年7月24日,长生生物（股票代码：002680）已经连续7个跌停,市值蒸发百亿以上。
The vaccine record fraud by Changchun Changsheng Biotechnology Co., Ltd has been generating negative impact, and Changsheng Biotechnology LLC, its listed parent company, has been tagged as an ST stock that may be delisted at any time, but never should investors foot the bill for the losses caused by corporate fraud.
出处
《法人》
2018年第8期76-78,96,共3页
Faren Magazine
